NEW YORK (GenomeWeb) – CRISPR Therapeutics announced today that it has raised an additional $38 million as part of a Series B Financing round.

The company said the funding round raised almost $140 million overall, with the first part of the financing being led by Vertex Pharmaceuticals and Bayer Global Investments, and the second, oversubscribed closing including new institutional investors and specialized healthcare funds such as Franklin Templeton Investments, New Leaf Venture Partners, and funds advised by Clough Capital Partners and Wellington Capital Management.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.